Novo Nordisk, Eli Lilly and the GLP-1 economy
Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period. It's been an awesome run for these companies. But how much longer can it last? Today on the show, Rob Armstrong and Aiden Reiter talk to the FT’s US pharmaceutical and biotech correspondent Oliver…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Unhedged →
Money Talks: Why weight-loss drugs will reshape the world
Novo Nordisk hits back at copycat drugs
Here's How the New Weight Loss Drugs Could Change Everything
The State of Weight-Loss Drugs
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.